Abstract: The disclosed Off-Road Vehicle Vision Enhancement System is for all terrain vehicles operating in extreme off road environments. When an all terrain vehicle is operating in areas where there are large obstacles to traverse the operator needs to be able to maneuver the vehicle over the obstacles with the utmost of care and precision. The operator needs to be able to see the precise placement of the wheels over the obstacles to achieve optimum ground clearance and avoid getting hung-up. The Off-Road Vision Enhancement System includes a retractable protective housing located under the vehicle containing cameras which communicate to the operator the precise relationship of his wheels traversing the obstacles. The retractable housing is designed for simple operation, maximum protection of the cameras and self cleaning of accumulated debris.

Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The disclosed Off-Road Vehicle Vision Enhancement System is for all terrain vehicles operating in extreme off road environments. When an all terrain vehicle is operating in areas where there are large obstacles to traverse the operator needs to be able to maneuver the vehicle over the obstacles with the utmost of care and precision. The operator needs to be able to see the precise placement of the wheels over the obstacles to achieve optimum ground clearance and avoid getting hung-up. The Off-Road Vision Enhancement System includes a retractable protective housing located under the vehicle containing cameras which communicate to the operator the precise relationship of his wheels traversing the obstacles. The retractable housing is designed for simple operation, maximum protection of the cameras and self cleaning of accumulated debris.

Abstract: A mixer/feeder wagon (1) for mixing and dispensing batches of animal feed comprises a device (50) for monitoring operation of the mixer/feeder wagon (1) and for determining instants during a mixing cycle during which ingredients of the animal feed are to be loaded into the mixer/feeder wagon (1). The mixer/feeder wagon (1) comprises a mixing compartment (14) within which a paddle mixer (17) is rotatable for mixing the ingredients of the batch of animal feed therein. Load sensors (9) produce signals indicative of the current weight of the ingredients in the mixing compartment (14) which are read by a microprocessor (55) of the device (50). A proximity sensor (38) counts the number of revolutions of the paddle mixer 17.

Abstract: A batch of animal feed from a plurality of ingredients is prepared in a mixer/feeder wagon (1) where the ingredients require respective predefined mixing periods during a mixing cycle in the mixer/feeder wagon (1). The mixer/feeder wagon (1) comprises a mixing compartment (14) in which a mixing rotor provided by a paddle mixer (17) is rotatably mounted. Stationary chopping blades (42) mounted in a base (43) of the mixing compartment (14) cooperate with the paddle mixer (17) for chopping fibrous material during the mixing cycle. The appropriate predefined mixing periods required for the respective ingredients are determined in order to avoid over-mixing and under-mixing of the ingredients, and the predefined mixing period is defined as the number of revolutions of the paddle mixer (17) to which that ingredient is to be subjected.

Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The invention relates to substituted azacycloalka?e compounds useful in treating conditions of the Central Nervous System (CNS); a pharmaceutical composition comprising same; a method of treating such conditions and of treating conditions in which inhibition of beta-secretase is indicated.

Abstract: The present invention relates to compounds of formula I The substituent designations are as disclosed. At least one of B, Q, D and E is nitrogen. The present invention also provides a method of treating disorders of the Central Nervous System such as schizophrenia and cognitive dysfunction.

Abstract: A mechanism for determining whether an image is of lossy-origin or lossless origin is used to maximize the compression ratio of any future compressions and avoid wasting the precious resources associated with lossless compression/decompression on any image that has previously been subjected to lossy compression/decompression.

Abstract: A method of treating overactive bladder disorders characterized by involuntary neurogenic detrusor contractions associated with the pathology of multiple sclerosis by administering fluoroalkoxybenzylamino derivatives of nitrogen containing heterocyclic compounds, and specifically, by administering compounds of the formula wherein Q, X1, X2 and X3 are as defined below, and their pharmaceutically acceptable salts.

Abstract: A method for protecting and merging a cantilevered flexure. In accordance with various embodiments. A carrier support surface supports a distal end of a cantilevered flexure. A merge support surface of a merge tool is aligned with a medial portion of the flexure. The merge support surface is used to displace the distal end of the flexure from the carrier support surface and to advance a transducer supported by said distal end to a final position.

Abstract: A device is described, including a first diffusion region having a first terminal, a second diffusion region having a second terminal, and a channel region disposed between the first diffusion region and the second diffusion region. Further, the first terminal and the second terminal are offset to enable a non-Manhattan current flow. A system is also described, including the previously described device and a second transistor. The pathway for the flow of the majority of the current carriers in the device defines a first direction. The second transistor also has at least two terminals, and a pathway for a majority of current carriers between the two terminals defines a second direction. The angle between the first direction and the second direction is nonzero and acute.

Abstract: The present invention is a method for representation of sign in an encoding scheme. An embodiment of the present invention provides a variable bit length binary representation of the absolute value of integer data and then appends a single bit representing the sign of the original integer data. According to one embodiment, the present invention uses the trailing sign bit to specify the sign of the integer being coded. This scheme is much simpler to encode and decode than other schemes that use sign representations for variable-length bit sequences, especially for data that is roughly symmetric about zero, or can be efficiently mapped to this rough symmetry. In another embodiment, if the present invention is used on data sets where there is a most frequently occurring value, the locations of the most frequently recurring value are exhaustively cataloged through some other means, and the variable-length codes are modified to remove the representation of this value.

Abstract: The present invention relates to certain benzoamide piperidine containing compounds and related compounds that exhibit activity as NK-1 receptor antagonists, (e.g., substance P receptor antagonists), to pharmaceutical compositions containing them, and to their use in the treatment and prevention of central nervous system disorders, inflammatory disorders, cardiovascular disorders, ophthalmic disorders, gastrointestinal disorders, disorders caused by helicobacter pylori, disorders of the immune system, urinary incontinence, pain, migraine, emesis, angiogenesis and other disorders.

Abstract: A mechanism is provided that identifies certain classes of images that are likely to be re-used, and utilizes this information to manage a cache better. This may include flushing certain classes of images that are less likely to be re-used before flushing the classes that are more likely to be reused. In addition, or alternatively, other factors regarding the image may be utilized to determine whether or not caching of the image should occur.

Abstract: An apparatus for protecting and merging a head stack assembly with a disc stack of a data storage device. The head stack assembly comprises a cantilevered flexure which supports a transducer at a distal end thereof. A carrier includes a carrier support surface arranged to contactingly support the distal end of the flexure. A merge tool is adapted to merge the transducer with a recording surface of the disc stack. The merge tool includes a merge support surface arranged to contactingly support a medial portion of the flexure while the carrier support surface is disposed between the merge support surface and the transducer. The transducer is merged by aligning the merge support surface with the medial portion of the flexure, and using the merge support surface to displace the distal end of the flexure from the carrier support surface and advance the transducer to a final position.

Abstract: The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant ?7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant ?7 nicotinic receptor agonist.

Abstract: The present invention provides a method and apparatus for distributed intraframe transmission. In one embodiment of the present invention, digital images are divided into regions. In this embodiment, an I-frame is not transmitted all at once. Instead, in each transmission, a region of the image is compressed without using interframe compression while the rest of the image is compressed using interframe compression. The region transmitted without interframe compression changes with each transmission. Thus, over the course of several transmissions every region of the image is transmitted without interframe compression. A transmission schedule controls the transmission of I-frame data for an entire image over the course of several frame transmissions. In one embodiment, a digital image is divided into M regions, and one region is transmitted without using interframe compression in each frame.

Abstract: Pharmaceutical compositions are disclosed for the treatment of attention deficit hyperactivity disorder (ADHD). The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an anti-ADHD agent and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.